Donepezil in Vascular Dementia: Combined Analysis of Two Large-Scale Clinical Trials
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background and Objective: There are currently no drugs approved to treat vascular dementia (VaD).The objective of this study was to determine if treatment with donepezil, an acetylcholinesterase inhibitor, may provide benefit for VaD patients. Methods: Combined analysis of 2 identical randomized, double-blind, placebo-controlled, 24-week studies involving 1,219 patients enrolled at 109 investigational sites in the USA, Europe, Canada and Australia. Patients were randomized to receive donepezil 5 mg/day (n = 406) or 10 mg/day (after brief titration; n = 421) or placebo (n = 392). Patients were assessed on cognition [Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS[-]cog), Mini-Mental State Examination (MMSE)], global function [Clinician’s Interview- Based Impression of Change plus (CIBIC[-]plus), Clinical Dementia Rating – Sum of the Boxes (CDR[-]SB)] and function [Alzheimer’s Disease Functional Assessment and Change Scale (ADFACS); instrumental activities of daily living (ADFACS[-]IADL)].Results:Both donepezil groups showed significant improvements in cognition compared with placebo (ADAS-cog, MMSE, p< 0.01). Significant global function benefits were seen on the CIBIC-plus in the 5 mg/day group (placebo vs. 5 mg/day, p < 0.001; vs. 10 mg/day, p = 0.006) and on the CDR-SB in the 10 mg/day group (placebo vs. 5 mg/day, p = 0.09; vs. 10 mg/day, p< 0.01). Significant functional benefits were also seen (ADFACS, placebo vs. 5 mg/day, p = 0.08; vs. 10 mg/day, p = 0.02; ADFACS-IADL, p < 0.05 for both donepezil groups). Donepezil was well tolerated, with low withdrawal rates due to adverse events. Conclusions: This combined analysis of the largest trial on VaD to date showed that donepezil-treated patients had significant benefits in cognition, global function and ability to perform IADL. Based on these findings and reported tolerability, donepezil should be considered as an important therapeutic element in the overall management of patients with VaD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subsequent study of “pure” VaD patients (n=788) showed cognitive treatment benefits, including benefit for an executive measure but not for daily functions; however, there was an overall trend for global benefit (P=0.06).401”
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 647
Self-citationOrgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
Mohs, R. C., Doody, R. S., Morris, J. C., Ieni, J. R., Rogers, S. L., Perdomo, C. A., Pratt, R. D., & for the “312” Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.481 · Cited by 503
Self-citationDonepezil in vascular dementia: A randomized, placebo-controlled study
Wilkinson, D., Doody, R., Helme, R., Taubman, K., Mintzer, J., Kertesz, A., Pratt, R. D., & the Donepezil 308 Study Group* (2003) · Neurology · doi:10.1212/01.wnl.0000078943.50032.fc · Cited by 392
Self-citationBlack, S., Román, G. C., Geldmacher, D. S., Salloway, S., Hecker, J., Burns, A., Perdomo, C., Kumar, D., & Pratt, R. (2003) · Stroke · doi:10.1161/01.str.0000091396.95360.e1 · Cited by 386
Self-citationDifferentiation of vascular dementia from AD on neuropsychological tests
Looi, J. C. L., & Sachdev, P. S. (1999) · Neurology · doi:10.1212/wnl.53.4.670 · Cited by 382
Wilcock, G., M??bius, H. J., & St??ffler, A. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00005 · Cited by 381
Efficacy and Safety of Cholinesterase Inhibitors in Alzheimer’s Disease: A Meta-analysis
Lane, C. E., & Conroy, M. L. (2022) · Essential Reviews in Geriatric Psychiatry · doi:10.1007/978-3-030-94960-0_53 · Cited by 324
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Ferris, S. H., Schmitt, F. A., Grundman, M., & Thomas, R. G. (1997) · Alzheimer Disease · doi:10.1007/978-1-4612-4116-4_64 · Cited by 303
Self-citationVascular dementia revisited: Diagnosis, pathogenesis, treatment, and prevention
Román, G. C. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00008-1 · Cited by 167
Self-citationCholinergic denervation in a pure multi-infarct state: Observations on CADASIL
Mesulam, M. M., Siddique, T., & Cohen, B. (2003) · Neurology · doi:10.1212/01.wnl.0000055927.22611.eb · Cited by 158
Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease
Rockwood, K. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.029074 · Cited by 135
Cognitive and motor impairments predict functional declines in patients with vascular dementia
Boyle, P. A., Cohen, R. A., Paul, R. H., Moser, D. J., & Gordon, N. M. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.539 · Cited by 111
Swartz, R. H., Sahlas, D. J., & Black, S. E. (2003) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1053/jscd.2003.5 · Cited by 110
Self-citationMortality in patients with dementia after ischemic stroke
Desmond, D. W., Moroney, J. T., Sano, M. C., & Stern, Y. (2002) · Neurology · doi:10.1212/wnl.59.4.537 · Cited by 106
Comparative Evolution of Alzheimer Disease, Vascular Dementia, and Mixed Dementia
Bowler, J. V., Eliasziw, M., Steenhuis, R., Munoz, D. G., Fry, R., Merskey, H., & Hachinski, V. C. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550180021007 · Cited by 75
Long-Term Cholinesterase Inhibitor Treatment of Alzheimer???s Disease
Johannsen, P. (2004) · CNS Drugs · doi:10.2165/00023210-200418120-00001 · Cited by 70
Pratt, R. D. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00266-6 · Cited by 32
Kittner, B., Deyn, P. P. D., & Erkinjuntti, T. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06410.x · Cited by 27
Number Needed to Treat ( NNT )
Bender, R. (2005) · Wiley eBooks · doi:10.1002/0470011815.b2a04032 · Cited by 23
Research works printed but not linked: 1
- 10.1001%2Fjama.277.11.925 · doi:10.1001/jama.277.11.925 · Paper page
Cited by
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Self-citationWhite matter hyperintensities, cognitive impairment and dementia: an update
Prins, N. D., & Scheltens, P. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.10 · Cited by 1,284
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.002 · Cited by 603
Kavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
Gitlin, L. N., Winter, L., Dennis, M. P., Hodgson, N., & Hauck, W. W. (2010) · JAMA · doi:10.1001/jama.2010.1253 · Cited by 367
Metadata
- Authors
- Román, G. C., Wilkinson, D. G., Doody, R. S., Black, S. E., Salloway, S. P., & Schindler, R. J.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Moorgreen Hospital (GB)
- Baylor College of Medicine (US)
- Sunnybrook Health Science Centre (CA)
- Brown University (US)
- Pfizer (United States) (US)
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2005
- Volume
- 20
- Issue
- 6
- Pages
- 338-344
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W2144769321
- Cited by
- 141
- References
- 25
- Citations by year
- 2025: 1 · 2024: 3 · 2022: 3 · 2021: 5 · 2020: 33 · 2019: 1 · 2018: 3 · 2017: 5 · 2016: 5 · 2015: 7 · 2014: 2 · 2013: 10 · 2012: 3
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Dementia and Geriatric Cognitive Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- donepezil, vascular dementia, acetylcholinesterase inhibitors, cognitive function, global function, instrumental activities of daily living, dose comparison, tolerability
- MeSH terms
- Donepezil, Activities of Daily Living, Aged, Cholinesterase Inhibitors, Clinical Protocols, Double-Blind Method, Drug Administration Schedule, Female, Humans, Indans, Male, Piperidines, Dementia, Vascular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.